Lung Cancer

Chicago, IL—Alectinib (Alecensa), a next-generation anaplastic lymphoma kinase (ALK) inhibitor, was called a new standard of care for patients with ALK mutation–positive non–small-cell lung cancer (NSCLC), based on results of the phase 3 ALEX clinical trial, which were presented at the 2017 ASCO annual meeting.
Chicago, IL—Osimertinib (Tagrisso) extends progression-free survival (PFS) compared with standard chemotherapy in patients with EGFR T790M mutation–positive non–small-cell lung cancer (NSCLC) who have central nervous system (CNS) metastases, reported Marina C. Garassino, MD, Thoracic Oncology Unit, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, at the 2017 ASCO annual meeting.
Dr. Edward Garon discusses the importance of smoking cessation programs for patients diagnosed with lung cancer.
Dr. Edward Garon talks about the best approaches for screening patients for lung cancer.
Dr. Edward Garon identifies the target population for lung cancer screening.
Dr. Edward Garon provides an overview of the most common presenting clinical features in adults with non-small cell lung cancer (NSCLC).
Dr. Edward Garon reviews how certain drugs can change the landscape for treating patients with lung cancer.
Dr. Edward Garon discusses the use of PD-1 and PD-L1 inhibitors in patients with lung cancer.
Dr. Edward Garon does not believe there is much value in utilizing PD-L1 inhibitors for pateints with ALK gene rearrangement.
Dr. Edward Garon speaks about how differences in patient populations with lung cancer can make it difficult to interpret and act on data.
Page 1 of 3
Results 1 - 10 of 26
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME